Shares of 23andme stocks fell more than 57% Monday after the San Francisco-based genetics company announced late Sunday it had filed for bankruptcy and its chief executive had resigned.
CEO Anne Wojcicki, who will remain on the board, has failed multiple times to rescue the flagging business by trying to buy it back.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.